SIA FUNDS, EL FONDO QUE CONFÍA EN GRÍFOLS SE POSICIONA EN CONTRA DE LA OPA .: PharmaMar Announces Data Presentations For Both Its Molecules Yondelis® , Aplidin Overall survival (OS) results of randomized phase III study (ADMYRE trial) and Lurbinectedin at ASCO 2018 .